Company profile
SQZ Biotechnologies Company
OTC: SQZB · Healthcare · Biotechnology
#540 of 1,422 Healthcare companies by revenue28th-percentile growth
EA Score
——FH —DQ 40GM —SS 36
v0.1 · 25/100 weight · pillars only
↑ growth stability, filing timeliness · ↓ Piotroski F, disclosure history
Methodology →Revenue TTM
$12.1M
Rev growth YoY (TTM)
-44.6%
Net income (FY)
-$79.5M
Employees
53
as of 2026-08-26
Market cap
$707.8k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$21.5M$21.5M2022
Net income-$79.5M-$79.5M2022
Operating income-$80.7M-$80.7M2022
Total assets$99.9M$99.9M2022
Liabilities$42.8M$42.8M2022
Equity$57.1M$57.1M2022
Revenue trend
FY2020 – FY2022 · USD
FY20
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is SQZ Biotechnologies Company’s revenue?
SQZ Biotechnologies Company booked $21.5M in FY2022 revenue, contracting 21% year over year — slower than 72% of Healthcare companies we track, at a -370.0% net margin.
Peers · Healthcare
DarioHealth Corp.49DAyurcann Holdings Corp.57CItem 9 Labs Corp.——Alector, Inc.40DMaxCyte, Inc.48DSCYNEXIS, Inc.60CNeighbors
Middlesex →Key facts
CEOHoward Bernstein
SectorHealthcare
IndustryBiotechnology
HeadquartersWatertown, MA
ExchangeOTC: SQZB
Employees53
IPO date2020-10-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.